Ru, Y.; Ma-Lauer, Y.; Xiang, C.; Li, P.; von Brunn, B.; Richter, A.; Drosten, C.; Pichlmair, A.; Pfefferle, S.; Klein, M.;
et al. LMP7 as a Target for Coronavirus Therapy: Inhibition by Ixazomib and Interaction with SARS-CoV-2 Proteins Nsp13 and Nsp16. Pathogens 2025, 14, 871.
https://doi.org/10.3390/pathogens14090871
AMA Style
Ru Y, Ma-Lauer Y, Xiang C, Li P, von Brunn B, Richter A, Drosten C, Pichlmair A, Pfefferle S, Klein M,
et al. LMP7 as a Target for Coronavirus Therapy: Inhibition by Ixazomib and Interaction with SARS-CoV-2 Proteins Nsp13 and Nsp16. Pathogens. 2025; 14(9):871.
https://doi.org/10.3390/pathogens14090871
Chicago/Turabian Style
Ru, Yi, Yue Ma-Lauer, Chengyu Xiang, Pengyuan Li, Brigitte von Brunn, Anja Richter, Christian Drosten, Andreas Pichlmair, Susanne Pfefferle, Markus Klein,
and et al. 2025. "LMP7 as a Target for Coronavirus Therapy: Inhibition by Ixazomib and Interaction with SARS-CoV-2 Proteins Nsp13 and Nsp16" Pathogens 14, no. 9: 871.
https://doi.org/10.3390/pathogens14090871
APA Style
Ru, Y., Ma-Lauer, Y., Xiang, C., Li, P., von Brunn, B., Richter, A., Drosten, C., Pichlmair, A., Pfefferle, S., Klein, M., Damoiseaux, R. D., Betz, U. A. K., & von Brunn, A.
(2025). LMP7 as a Target for Coronavirus Therapy: Inhibition by Ixazomib and Interaction with SARS-CoV-2 Proteins Nsp13 and Nsp16. Pathogens, 14(9), 871.
https://doi.org/10.3390/pathogens14090871
